Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Next-generation sequencing studies have significantly improved our understanding of the chronic lymphocytic leukemia (CLL) genetic landscape, tumor architecture and allowed the identification of associations between specific mutations and clinical outcome. Hence, mutations in TP53, NOTCH1, SF3B1, BIRC3, EGR2 and MYD88 are known to be associated with differential prognosis. Despite the work performed on these genes, several additional putative tumor-driver genes are recurrently mutated in CLL, but their clinical impact remains unclear.